Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Murine breast-cancer-cell/mesenchymal-stem-cell hybrids exhibit enhanced drug resistance to different cytostatic drugs.

Nagler C, Zänker KS, Dittmar T.

J Stem Cells Regen Med. 2010 Oct 23;6(2):133. eCollection 2010. No abstract available.

PMID:
24693142
2.

Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity.

Rappa G, Mercapide J, Lorico A.

Am J Pathol. 2012 Jun;180(6):2504-15. doi: 10.1016/j.ajpath.2012.02.020. Epub 2012 Apr 27.

3.

Tumor associated macrophage × cancer cell hybrids may acquire cancer stem cell properties in breast cancer.

Ding J, Jin W, Chen C, Shao Z, Wu J.

PLoS One. 2012;7(7):e41942. doi: 10.1371/journal.pone.0041942. Epub 2012 Jul 25.

4.

Characterization of hybrid cells derived from spontaneous fusion events between breast epithelial cells exhibiting stem-like characteristics and breast cancer cells.

Dittmar T, Schwitalla S, Seidel J, Haverkampf S, Reith G, Meyer-Staeckling S, Brandt BH, Niggemann B, Zänker KS.

Clin Exp Metastasis. 2011 Jan;28(1):75-90. doi: 10.1007/s10585-010-9359-3. Epub 2010 Oct 28.

PMID:
20981475
5.

Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.

Leth-Larsen R, Terp MG, Christensen AG, Elias D, Kühlwein T, Jensen ON, Petersen OW, Ditzel HJ.

Mol Med. 2012 Sep 25;18:1109-21. doi: 10.2119/molmed.2012.00091.

6.

Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties.

Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM.

Stem Cells. 2012 Feb;30(2):292-303. doi: 10.1002/stem.791.

7.

Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance.

Mallini P, Lennard T, Kirby J, Meeson A.

Cancer Treat Rev. 2014 Apr;40(3):341-8. doi: 10.1016/j.ctrv.2013.09.008. Epub 2013 Sep 15. Review.

PMID:
24090504
8.

Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.

Liu H, Zhang HW, Sun XF, Guo XH, He YN, Cui SD, Fan QX.

Chin Med J (Engl). 2013 Aug;126(16):3030-4.

10.

Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.

May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA.

Breast Cancer Res. 2011 Feb 8;13(1):202. doi: 10.1186/bcr2789. Review.

11.

FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.

Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA.

Cancer Res. 2013 Mar 15;73(6):1981-92. doi: 10.1158/0008-5472.CAN-12-2962. Epub 2013 Feb 1.

12.

The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression.

Houthuijzen JM, Daenen LG, Roodhart JM, Voest EE.

Br J Cancer. 2012 Jun 5;106(12):1901-6. doi: 10.1038/bjc.2012.201. Epub 2012 May 17. Review.

13.

Endothelial induced EMT in breast epithelial cells with stem cell properties.

Sigurdsson V, Hilmarsdottir B, Sigmundsdottir H, Fridriksdottir AJ, Ringnér M, Villadsen R, Borg A, Agnarsson BA, Petersen OW, Magnusson MK, Gudjonsson T.

PLoS One. 2011;6(9):e23833. doi: 10.1371/journal.pone.0023833. Epub 2011 Sep 6.

14.

Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway.

Ahn HJ, Kim G, Park KS.

Biochem Biophys Res Commun. 2013 Aug 9;437(4):557-64. doi: 10.1016/j.bbrc.2013.06.114. Epub 2013 Jul 9.

PMID:
23850691
15.

Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance.

Pinto CA, Widodo E, Waltham M, Thompson EW.

Cancer Lett. 2013 Nov 28;341(1):56-62. doi: 10.1016/j.canlet.2013.06.003. Epub 2013 Jul 2. Review.

PMID:
23830804
16.

Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells.

Lee KD, Pai MY, Hsu CC, Chen CC, Chen YL, Chu PY, Lee CH, Chen LT, Chang JY, Huang TH, Hsiao SH, Leu YW.

Biochem Biophys Res Commun. 2012 Jun 15;422(4):578-85. doi: 10.1016/j.bbrc.2012.05.029. Epub 2012 May 14.

PMID:
22595458
17.

Blockade of Autocrine TGF-β Signaling Inhibits Stem Cell Phenotype, Survival, and Metastasis of Murine Breast Cancer Cells.

Liu Z, Bandyopadhyay A, Nichols RW, Wang L, Hinck AP, Wang S, Sun LZ.

J Stem Cell Res Ther. 2012 Feb 19;2(1):1-8.

18.

Establishment and characterization of new murine breast cancer cell lines.

Bernhardt G, Beckenlehner K, Spruss T, Schlemmer R, Reile H, Schönenberger H.

Arch Pharm (Weinheim). 2002 Mar;335(2-3):55-68.

PMID:
12043456
19.
20.

Characterization of new potential anticancer drugs designed to overcome glutathione transferase mediated resistance.

Johansson K, Ito M, Schophuizen CM, Mathew Thengumtharayil S, Heuser VD, Zhang J, Shimoji M, Vahter M, Ang WH, Dyson PJ, Shibata A, Shuto S, Ito Y, Abe H, Morgenstern R.

Mol Pharm. 2011 Oct 3;8(5):1698-708. doi: 10.1021/mp2000692. Epub 2011 Aug 30.

PMID:
21851097
Items per page

Supplemental Content

Write to the Help Desk